#United States #New York #Gross Law Firm #Sana Biotechnology #SANA

Investor Alert: Lead Plaintiff Deadline Approaches for Sana Biotechnology

The Gross Law Firm has issued an important notice for shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Those who purchased shares between March 17, 2023, and November 4, 2024, should be aware of a crucial deadline approaching on May 20, 2025. This date marks the last opportunity for potential lead plaintiffs to step forward in a class action lawsuit concerning allegations of securities fraud.

Background of the Case

The allegations center around claims that the company may have misled investors regarding several factors impacting its financial health and operational capabilities. Specifically, the lawsuit articulates that Sana Biotechnology allegedly:

1. Understated financial risks: It is claimed that Sana did not adequately disclose that it was at significant risk of operating without sufficient funds to sustain its current business model and advance its various product candidates.
2. Misrepresented product potentials: The complaint stipulates that certain products, specifically SC291 in oncology, SC379, and SG299, were portrayed as more promising than was truthful. Investors were allegedly led to believe these products would significantly advance, which has now been called into question.
3. Funding reductions: The lawsuit suggests that in an effort to conserve cash and prioritize product lines deemed more viable, Sana might reduce funding or even halt operations for some of its lesser products along with a potential layoff of a significant number of employees.
4. Overstated financial capacity: As a result of the aforementioned claims, the defendants are charged with having inflated Sana's financial stability publically, presenting a misleading image of the company's ability to continue operations effectively.

What Should Shareholders Do?

Shareholders who invested in SANA during the specified class period are strongly encouraged to contact the Gross Law Firm promptly to explore their options regarding participation as lead plaintiffs in the case. It’s essential to act quickly as the May 20, 2025 deadline is fast approaching. Registering for this class action will not incur any costs, and being a lead plaintiff is not a requirement to benefit from a potential recovery.

Once registered, shareholders will gain access to a portfolio monitoring software that provides periodic updates on the progress of the case. This measure ensures that investors are well-informed as the litigation unfolds.

Why Choose the Gross Law Firm?

The Gross Law Firm is recognized nationally for its commitment to justice on behalf of investors. The firm prides itself on defending the rights of individuals who have incurred losses as a result of fraudulent activities and illegal business practices. It aims to hold companies accountable and ensure adherence to ethical corporate standards, maintaining corporate integrity in the marketplace. Their extensive experience in class action cases gives shareholders confidence that their rights and financial interests are in capable hands.

For further information or to begin the registration process, shareholders can visit the Gross Law Firm’s website or contact them directly at the following:

• - Address: 15 West 38th Street, 12th floor, New York, NY 10018
• - Email: info@grosslawfirm.com
• - Phone: (646) 453-8903

Conclusion

The upcoming deadline of May 20, 2025, presents a critical opportunity for those impacted by the alleged misrepresentations from Sana Biotechnology. Taking proactive steps now will ensure shareholders are equipped to assert their rights as the case develops. Don’t miss out on the chance for recovery if you purchased shares during the specified period. The Gross Law Firm is here to assist you with any questions regarding this process.